There are no data regarding overdose with dostarlimab. Symptoms of overdosage are likely to be consistent with the adverse effect profile of dostarlimab and may therefore involve significant immune-mediated reactions.L33320
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).L33320 PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt to destroy the cancerous cells.A234379 Agents acting on the PD-1 pathway, such as nivolumab and pembrolizumab, facilitate endogenous immune-mediated anti-tumor activity and may therefore be used to treat a wide variety of cancers, including those of the skin, lung, kidneys, and liver.
In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer experiencing disease progression despite treatment with platinum-containing chemotherapy regimens.L33340 A companion diagnostic device - the VENTANA MMR RxDx Panel - was also approved alongside this indication to select appropriate patients for treatment.L33340 This indication was granted full FDA approval on February 10, 2023.L45161 Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month.L45156
Dostarlimab is currently under investigation for the treatment of rectal cancers with mismatch repair deficiency. A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.A248905
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Dostarlimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Dostarlimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Dostarlimab. |
| Estrone | Estrone may increase the thrombogenic activities of Dostarlimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Dostarlimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Dostarlimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Dostarlimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Dostarlimab. |
| Estriol | Estriol may increase the thrombogenic activities of Dostarlimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Dostarlimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Dostarlimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Dostarlimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Dostarlimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dostarlimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dostarlimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Dostarlimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Dostarlimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Dostarlimab. |
| Equol | Equol may increase the thrombogenic activities of Dostarlimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Dostarlimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Dostarlimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Dostarlimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Dostarlimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Dostarlimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Dostarlimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Dostarlimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Dostarlimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Dostarlimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Dostarlimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Dostarlimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Dostarlimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dostarlimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Dostarlimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Dostarlimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Dostarlimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dostarlimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dostarlimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Dostarlimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dostarlimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Dostarlimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Dostarlimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Dostarlimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dostarlimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dostarlimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Dostarlimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dostarlimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dostarlimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dostarlimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dostarlimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Dostarlimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Dostarlimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dostarlimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dostarlimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dostarlimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Dostarlimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Dostarlimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dostarlimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Dostarlimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Dostarlimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Dostarlimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Dostarlimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Dostarlimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Dostarlimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Dostarlimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Dostarlimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Dostarlimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Dostarlimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Dostarlimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Dostarlimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Dostarlimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Dostarlimab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dostarlimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Dostarlimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dostarlimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Dostarlimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Dostarlimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Dostarlimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Dostarlimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Dostarlimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Dostarlimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Dostarlimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dostarlimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Dostarlimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Dostarlimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dostarlimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dostarlimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Dostarlimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Dostarlimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dostarlimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Dostarlimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Dostarlimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Dostarlimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Dostarlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Dostarlimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Dostarlimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Dostarlimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Dostarlimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dostarlimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Dostarlimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Dostarlimab. |